Abionic's New POC Sepsis Test On Rapid Move To Market
Executive Summary
Swiss start-up Abionic has CE marked rapid tests for sepsis and iron deficiency, designed to run on its diagnostics platform abioSCOPE. The new sepsis test is based on a new biomarker PSP which has shown to be superior to current tests in detecting this life threatening condition early.
You may also be interested in...
Abionic Scores $21m To Push Through 5-Min Sepsis Test
Swiss diagnostics developer Abionic has scored CHF20m ($21m) in Series C financing from a syndicate of high-net-worth individuals to kickstart a multinational study into the efficacy of its Pancreatic Stone Protein (PSP) test for rapid sepsis risk assessment and management.
OUS Approvals Analysis: Medtronic, Abbott, Abionic Lead 2017 Upswing
The 20 non-US medical device approvals in January, including eight in in vitro diagnostics, four in orthopedics, and three in cardiovascular devices. Big medtech players Medtronic and Abbott, accompanied by much smaller Swiss IVD firm Abionic, led the charge and bagged more OUS approvals than most.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.